Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

How to Define Early COPD.

Agusti A, Faner R.

Am J Respir Crit Care Med. 2018 Jul 18. doi: 10.1164/rccm.201805-0880LE. [Epub ahead of print] No abstract available.

PMID:
30020809
2.

Bone marrow characterization in COPD: a multi-level network analysis.

Toledo-Pons N, Noell G, Jahn A, Iglesias A, Duran MA, Iglesias J, Rios A, Scrimini S, Faner R, Gigirey O, Agustí A, Cosío BG.

Respir Res. 2018 Jun 15;19(1):118. doi: 10.1186/s12931-018-0824-x.

3.

The Changing Landscape of COPD.

Agusti A, Faner R.

Am J Respir Crit Care Med. 2018 Apr 27. doi: 10.1164/rccm.201804-0714ED. [Epub ahead of print] No abstract available.

PMID:
29701997
4.

COPD beyond smoking: new paradigm, novel opportunities.

Agustí A, Faner R.

Lancet Respir Med. 2018 May;6(5):324-326. doi: 10.1016/S2213-2600(18)30060-2. Epub 2018 Feb 26. No abstract available.

PMID:
29496484
5.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

PMID:
29437944
6.

From systems biology to P4 medicine: applications in respiratory medicine.

Noell G, Faner R, Agustí A.

Eur Respir Rev. 2018 Feb 7;27(147). pii: 170110. doi: 10.1183/16000617.0110-2017. Print 2018 Mar 31.

7.

Hospitalizations due to exacerbations of COPD: A big data perspective.

Serra-Picamal X, Roman R, Escarrabill J, García-Altés A, Argimón JM, Soler N, Faner R, Carbonell EM, Trilla A, Agusti A.

Respir Med. 2018 Jan 16. pii: S0954-6111(18)30009-X. doi: 10.1016/j.rmed.2018.01.008. [Epub ahead of print]

PMID:
29398283
8.

Clinical News.

Hosgood S, Williams R, Brugada J, Agusti A, Faner R, Noell G.

Br J Hosp Med (Lond). 2018 Jan 2;79(1):8-11. doi: 10.12968/hmed.2018.79.1.8. No abstract available.

PMID:
29315044
9.

Towards a global initiative for fibrosis treatment (GIFT).

Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, Antoniou KM, Sellares J.

ERJ Open Res. 2017 Dec 1;3(4). pii: 00106-2017. doi: 10.1183/23120541.00106-2017. eCollection 2017 Oct.

10.

Lung function in early adulthood and health in later life: a transgenerational cohort analysis.

Agustí A, Noell G, Brugada J, Faner R.

Lancet Respir Med. 2017 Dec;5(12):935-945. doi: 10.1016/S2213-2600(17)30434-4. Epub 2017 Nov 14.

PMID:
29150410
11.

COPD: algorithms and clinical management.

Faner R, Agustí A.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701733. doi: 10.1183/13993003.01733-2017. Print 2017 Nov. No abstract available.

PMID:
29097436
12.

Precision medicine in airway diseases: moving to clinical practice.

Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701655. doi: 10.1183/13993003.01655-2017. Print 2017 Oct.

PMID:
29051276
13.

The EASI model: A first integrative computational approximation to the natural history of COPD.

Agustí A, Compte A, Faner R, Garcia-Aymerich J, Noell G, Cosio BG, Rodriguez-Roisin R, Celli B, Anto JM.

PLoS One. 2017 Oct 10;12(10):e0185502. doi: 10.1371/journal.pone.0185502. eCollection 2017.

14.

Multi-level differential network analysis of COPD exacerbations.

Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, Esteban C, Gea J, Rodriguez-Roisin R, Garcia-Nuñez M, Pozo-Rodriguez F, Kalko SG, Agustí A.

Eur Respir J. 2017 Sep 27;50(3). pii: 1700075. doi: 10.1183/13993003.00075-2017. Print 2017 Sep.

PMID:
28954781
15.

What does endotyping mean for treatment in chronic obstructive pulmonary disease?

Agustí A, Celli B, Faner R.

Lancet. 2017 Sep 2;390(10098):980-987. doi: 10.1016/S0140-6736(17)32136-0. Review.

PMID:
28872030
16.

Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers.

Obeidat M, Nie Y, Fishbane N, Li X, Bossé Y, Joubert P, Nickle DC, Hao K, Postma DS, Timens W, Sze MA, Shannon CP, Hollander Z, Ng RT, McManus B, Miller BE, Rennard S, Spira A, Hackett TL, Lam W, Lam S, Faner R, Agusti A, Hogg JC, Sin DD, Paré PD.

Am J Respir Cell Mol Biol. 2017 Oct;57(4):411-418. doi: 10.1165/rcmb.2016-0284OC.

PMID:
28459279
17.

The microbiome in respiratory medicine: current challenges and future perspectives.

Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, Manichanh C, Molyneaux PL, Paredes R, Pérez Brocal V, Ponomarenko J, Sethi S, Dorca J, Monsó E.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602086. doi: 10.1183/13993003.02086-2016. Print 2017 Apr. Review.

PMID:
28404649
18.

Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.

Huleihel L, Sellares J, Cardenes N, Álvarez D, Faner R, Sakamoto K, Yu G, Kapetanaki MG, Kaminski N, Rojas M.

Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L92-L103. doi: 10.1152/ajplung.00323.2016. Epub 2017 Apr 6.

19.

Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.

Faner R, Agustí Á.

Ann Am Thorac Soc. 2016 Dec;13(Supplement_5):S466-S470. doi: 10.1513/AnnalsATS.201605-372AW. Review.

PMID:
28005422
20.

The inflammasome pathway in stable COPD and acute exacerbations.

Faner R, Sobradillo P, Noguera A, Gomez C, Cruz T, López-Giraldo A, Ballester E, Soler N, Arostegui JI, Pelegrín P, Rodriguez-Roisin R, Yagüe J, Cosio BG, Juan M, Agustí A.

ERJ Open Res. 2016 Jul 11;2(3). pii: 00002-2016. eCollection 2016 Jul.

21.

Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema.

Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, Tal-Singer R, Miller B, Rodriguez-Roisin R, Spira A, Kalko SG, Agustí A.

Am J Respir Crit Care Med. 2016 Jun 1;193(11):1242-53. doi: 10.1164/rccm.201507-1311OC.

PMID:
26735770
22.

Network analysis: a way forward for understanding COPD multimorbidity.

Faner R, Agustí A.

Eur Respir J. 2015 Sep;46(3):591-2. doi: 10.1183/09031936.00054815. No abstract available.

23.

Molecular and clinical diseasome of comorbidities in exacerbated COPD patients.

Faner R, Gutiérrez-Sacristán A, Castro-Acosta A, Grosdidier S, Gan W, Sánchez-Mayor M, Lopez-Campos JL, Pozo-Rodriguez F, Sanz F, Mannino D, Furlong LI, Agusti A.

Eur Respir J. 2015 Oct;46(4):1001-10. doi: 10.1183/13993003.00763-2015. Epub 2015 Aug 6.

24.

Biomarkers, the control panel and personalized COPD medicine.

Agusti A, Gea J, Faner R.

Respirology. 2016 Jan;21(1):24-33. doi: 10.1111/resp.12585. Epub 2015 Jul 14. Review.

25.

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J.

N Engl J Med. 2015 Jul 9;373(2):111-22. doi: 10.1056/NEJMoa1411532.

26.

Fibrinogen and COPD: Now what?

Faner R, Agusti A.

Chronic Obstr Pulm Dis. 2015 Jan 24;2(1):1-3. doi: 10.15326/jcopdf.2.1.2014.0127. No abstract available.

27.

Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Agustí A, Antó JM, Auffray C, Barbé F, Barreiro E, Dorca J, Escarrabill J, Faner R, Furlong LI, Garcia-Aymerich J, Gea J, Lindmark B, Monsó E, Plaza V, Puhan MA, Roca J, Ruiz-Manzano J, Sampietro-Colom L, Sanz F, Serrano L, Sharpe J, Sibila O, Silverman EK, Sterk PJ, Sznajder JI.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):391-401. doi: 10.1164/rccm.201410-1935PP.

28.

HLA-DQ2/DQ8 and HLA-DQB1*02 homozygosity typing by real-time polymerase chain reaction for the assessment of celiac disease genetic risk: evaluation of a Spanish celiac population.

Ruiz-Ortiz E, Montraveta M, Cabré E, Herrero-Mata MJ, Pujol-Borrell R, Palou E, Faner R.

Tissue Antigens. 2014 Dec;84(6):545-53. doi: 10.1111/tan.12472.

PMID:
25413104
29.

Network medicine analysis of COPD multimorbidities.

Grosdidier S, Ferrer A, Faner R, Piñero J, Roca J, Cosío B, Agustí A, Gea J, Sanz F, Furlong LI.

Respir Res. 2014 Sep 24;15:111. doi: 10.1186/s12931-014-0111-4.

30.

Network medicine, multimorbidity and the lung in the elderly.

Faner R, Cruz T, López-Giraldo A, Agustí A.

Eur Respir J. 2014 Sep;44(3):775-88. doi: 10.1183/09031936.00078714. Epub 2014 Jul 25. Review.

31.

Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect.

Faner R, Gonzalez N, Cruz T, Kalko SG, Agustí A.

PLoS One. 2014 May 15;9(5):e97491. doi: 10.1371/journal.pone.0097491. eCollection 2014.

32.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators.

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5. Review.

PMID:
24310110
33.

Immune response in chronic obstructive pulmonary disease.

Faner R, Cruz T, Agusti A.

Expert Rev Clin Immunol. 2013 Sep;9(9):821-33. doi: 10.1586/1744666X.2013.828875. Review.

PMID:
24070046
34.

HLA distribution in COPD patients.

Faner R, Nuñez B, Sauleda J, Garcia-Aymerich J, Pons J, Crespí C, Milà J, González JR, Maria Antó J, Agusti A; PAC-COPD Study Group.

COPD. 2013 Apr;10(2):138-46. doi: 10.3109/15412555.2012.729621. Epub 2013 Mar 20.

PMID:
23514216
35.

An investigation of the resolution of inflammation (catabasis) in COPD.

Noguera A, Gomez C, Faner R, Cosio B, González-Périz A, Clària J, Carvajal A, Agustí A.

Respir Res. 2012 Nov 13;13:101. doi: 10.1186/1465-9921-13-101.

36.

Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Faner R, Rojas M, Macnee W, Agustí A.

Am J Respir Crit Care Med. 2012 Aug 15;186(4):306-13. doi: 10.1164/rccm.201202-0282PP. Epub 2012 May 10. Review.

PMID:
22582162
37.

Systemic inflammation and comorbidities in chronic obstructive pulmonary disease.

Agustí A, Faner R.

Proc Am Thorac Soc. 2012 May;9(2):43-6. doi: 10.1513/pats.201108-050MS. Review.

PMID:
22550240
38.

Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.

Colobran R, Armengol Mdel P, Faner R, Gärtner M, Tykocinski LO, Lucas A, Ruiz M, Juan M, Kyewski B, Pujol-Borrell R.

Hum Mol Genet. 2011 Sep 1;20(17):3415-23. doi: 10.1093/hmg/ddr247. Epub 2011 Jun 3.

PMID:
21642385
39.

CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity.

Pedrosa E, Carretero-Iglesia L, Boada A, Colobran R, Faner R, Pujol-Autonell I, Palou E, Esteve A, Pujol-Borrell R, Ferrándiz C, Juan M, Carrascosa JM.

J Invest Dermatol. 2011 Sep;131(9):1830-7. doi: 10.1038/jid.2011.127. Epub 2011 May 26.

40.

ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression.

Ballana E, Senserrich J, Pauls E, Faner R, Mercader JM, Uyttebroeck F, Palou E, Mena MP, Grau E, Clotet B, Ruiz L, Telenti A, Ciuffi A, Esté JA.

Clin Infect Dis. 2010 Apr 1;50(7):1022-32. doi: 10.1086/651114.

PMID:
20192730
41.

Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan M.

Eur J Immunol. 2010 Jan;40(1):91-102. doi: 10.1002/eji.200939225.

42.

High resolution definition of HLA-DRB haplotypes by a simplified microsatellite typing technique.

Doxiadis GG, de Groot N, Dauber EM, van Eede PH, Fae I, Faner R, Fischer G, Grubic Z, Lardy NM, Mayr W, Palou E, Swelsen W, Stingl K, Doxiadis II, Bontrop RE.

Tissue Antigens. 2009 Dec;74(6):486-93. doi: 10.1111/j.1399-0039.2009.01369.x. Epub 2009 Sep 24.

PMID:
19778321
43.

Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation.

Colobran R, Casamitjana N, Roman A, Faner R, Pedrosa E, Arostegui JI, Pujol-Borrell R, Juan M, Palou E.

Genes Immun. 2009 Apr;10(3):254-9. doi: 10.1038/gene.2008.96. Epub 2009 Jan 15.

PMID:
19148142
44.

Population structure in copy number variation and SNPs in the CCL4L chemokine gene.

Colobran R, Comas D, Faner R, Pedrosa E, Anglada R, Pujol-Borrell R, Bertranpetit J, Juan M.

Genes Immun. 2008 Jun;9(4):279-88. doi: 10.1038/gene.2008.15. Epub 2008 Mar 27.

PMID:
18368065
45.

Real-time PCR using fluorescent resonance emission transfer probes for HLA-B typing.

Faner R, Casamitjana N, Coll J, Caro P, Pujol-Borrell R, Palou E, Juan M.

Hum Immunol. 2006 Apr-May;67(4-5):374-85. Epub 2006 Apr 7.

PMID:
16720220
46.

Development of a new HLA-DRB real-time PCR typing method.

Casamitjana N, Faner R, Santamaria A, Colobran R, Ribera A, Pujol-Borrell R, Juan M, Palou E.

Hum Immunol. 2005 Jan;66(1):85-91.

PMID:
15620466
47.

HLA-B27 genotyping by fluorescent resonance emission transfer (FRET) probes in real-time PCR.

Faner R, Casamitjana N, Colobran R, Ribera A, Pujol-Borrell R, Palou E, Juan M.

Hum Immunol. 2004 Aug;65(8):826-38.

PMID:
15336784
48.

Recurrence of mandibular tori after surgical removal: two case reports.

Brunsvold MA, Kaiser DA, Faner RM.

J Prosthodont. 1995 Sep;4(3):164-7.

PMID:
8603205
49.

IgG subclasses in human periodontal disease. II. Cytophilic and membrane IgG subclass immunoglobulins.

Mackler BF, Faner RM, Schur P, Wright TE 3rd, Levy BM.

J Periodontal Res. 1978 Sep;13(5):433-44.

PMID:
151131

Supplemental Content

Support Center